14 research outputs found
Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts
Gastrointestinal (GI) bleeding is associated with considerable morbidity and
mortality. Red blood cell (RBC) transfusion has long been the cornerstone
of treatment for anemia due to GI bleeding. However, blood is not devoid
of potential adverse effects, and it is also a precious resource, with limited
supplies in blood banks. Nowadays, all patients should benefit from a
patient blood management (PBM) program that aims to minimize blood loss,
optimize hematopoiesis (mainly by using iron replacement therapy), maximize
tolerance of anemia, and avoid unnecessary transfusions. Integration of PBM
into healthcare management reduces patient mortality and morbidity and
supports a restrictive RBC transfusion approach by reducing transfusion rates.
The European Commission has outlined strategies to support hospitals with
the implementation of PBM, but it is vital that these initiatives are translated
into clinical practice. To help optimize management of anemia and iron
deficiency in adults with acute or chronic GI bleeding, we developed a
protocol under the auspices of the Spanish Association of Gastroenterology,
in collaboration with healthcare professionals from 16 hospitals across
Spain, including expert advice from different specialties involved in PBM
strategies, such as internal medicine physicians, intensive care specialists,
and hematologists. Recommendations include how to identify patients who
have anemia (or iron deficiency) requiring oral/intravenous iron replacement
therapy and/or RBC transfusion (using a restrictive approach to transfusion),
and transfusing RBC units 1 unit at a time, with assessment of patients after
each given unit (i.e., âdonât give two without reviewâ). The advantages and
limitations of oral versus intravenous iron and guidance on the safe and
effective use of intravenous iron are also described. Implementation of a PBM
strategy and clinical decision-making support, including early treatment of
anemia with iron supplementation in patients with GI bleeding, may improve
patient outcomes and lower hospital costs
Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studies
BACKGROUND: Pharmacogenetic studies are essential in understanding the interindividual variability of drug responses. DNA sample collection for genotyping is a critical step in genetic studies. A method using dried blood samples from finger-puncture, collected on DNA-cards, has been described as an alternative to the usual venepuncture technique. The purpose of this study is to evaluate the implementation of the DNA cards method in a multicentre clinical trial, and to assess the degree of investigators' satisfaction and the acceptance of the patients perceived by the investigators. METHODS: Blood samples were collected on DNA-cards. The quality and quantity of DNA recovered were analyzed. Investigators were questioned regarding their general interest, previous experience, safety issues, preferences and perceived patient satisfaction. RESULTS: 151 patients' blood samples were collected. Genotyping of GST polymorphisms was achieved in all samples (100%). 28 investigators completed the survey. Investigators perceived patient satisfaction as very good (60.7%) or good (39.3%), without reluctance to finger puncture. Investigators preferred this method, which was considered safer and better than the usual methods. All investigators would recommend using it in future genetic studies. CONCLUSION: Within the clinical trial setting, the DNA-cards method was very well accepted by investigators and patients (in perception of investigators), and was preferred to conventional methods due to its ease of use and safety
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
Distinct effects of human calcitonin gene-related peptide I and II on gastric blood flow and acid secretion in anesthetized rabbits
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia.
The purpose of the study was to evaluate the efficacy of preoperative intravenous (IV) ferric carboxymaltose (FCM) administration vs. no-IV iron in colon cancer (CC) anemic patients undergoing elective surgery with curative intention. This was a multicenter, observational study including two cohorts of consecutive CC anemic patients: the no-IV iron treatment group was obtained retrospectively while FCM-treated patients were recorded prospectively. A total of 266 patients were included: 111 received FCM (median dose 1000 mg) and 155 were no-IV iron subjects. Both groups were similar in terms of demographic characteristics, tumor location, surgical approach, and intra-operative bleeding severity. The FCM group showed a significant lower need for red blood cell (RBC) transfusion during the study (9.9 vs. 38.7%; OR: 5.9, pâ Preoperative ferric carboxymaltose treatment in patients with CC and iron deficiency anemia significantly reduced RBC transfusion requirements and hospital length of stay, reaching higher response rates and percentages of normalized hemoglobin levels both at hospital admission and 30 days post-surgery
Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia
Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding
Objective The aim of this study was to assess the efïŹcacy and safety of intravenous ferric carboxymaltose (FCM) following hospitalization for acute gastrointestinal bleeding (AGIB) in the context of a restrictive transfusion strategy. Patients and methods A retrospective single-center study analyzed patients with AGIB (excluding AGIB secondary to portal hypertension) administered a single FCM dose with or without blood transfusion. Results Eighty-six episodes in 84 patients were analyzed. Seventy-nine patients had upper AGIB. Nineteen episodes were associated with hemodynamic instability. FCM was administered during hospitalization as a single dose of 1000mg iron in 84/86 episodes and as a single dose of 500mg iron in two episodes, with blood transfusion in 60/86 (69.8%) episodes. The mean hemoglobin (Hb) was 9.0g/dl at admission, 7.6g/dl at the lowest in-hospital value, 9.4g/dl at discharge, and 12.7g/dl at followup (mean: 55 days postdischarge) (P<0.001 for follow-up vs. all other timepoints). The lowest mean in-hospital Hb value was 7.2 and 8.8g/dl, respectively, in patients with transfusion+FCM versus FCMalone; the mean Hb was 12.4 versus 13.7g/dl at followup. In patients administered FCM alone, the mean Hb at follow-up in the subpopulations aged older than or equal to 75 years (n=33), Charlson comorbidity index of at least 3 (n=48), and Hb of up to 10g/dl at admission (n=47) were 12.6, 13.1, and 13.3g/dl, respectively. No adverse effects were detected. Conclusion Treatment with FCM for AGIB is associated with a good erythropoietic response and anemia correction after hospitalization, even in severe episodes or when transfusion is needed. FCM is safe and well tolerated, and may support a restrictive transfusion policy. Eur J Gastroenterol Hepatol 31:116â12